BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:18:00 PM | Browse: 1060 | Download: 1239
Publication Name World Journal of Ophthalmology
Manuscript ID 11635
Country United States
Received
2014-05-29 09:52
Peer-Review Started
2014-05-29 22:36
To Make the First Decision
2014-07-29 12:01
Return for Revision
2014-07-30 10:26
Revised
2014-09-07 00:00
Second Decision
2014-10-27 16:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-10-27 17:02
Articles in Press
2014-10-27 17:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-04 16:41
Publish the Manuscript Online
2014-11-14 13:11
ISSN 2218-6239 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Ophthalmology
Manuscript Type Minireviews
Article Title Age-related macular degeneration treatment in the era of molecular medicine
Manuscript Source Invited Manuscript
All Author List Rick N Nordgren, Ahmed M Elkeeb and Bernard F Godley
Funding Agency and Grant Number
Corresponding Author Bernard F Godley, MD, PhD, MBA, FACS, Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555, United States. bgodley@utmb.edu
Key Words Age-related macular degeneration; Stem cell therapy; Anti-vascular endothelial growth factor; Gene therapy; Complement factor H; High-temperature requirement factor A1; Age-relateed maculopathy susceptibility 2; Pharmacogenomics; Genetics
Core Tip New therapies for age-related macular degeneration (AMD) such as stem cell transplantation and viral vector delivery are currently under intense investigation. Possible new treatments for both non-exudative and exudative AMD are on the horizon. Human embryonic stem cell derived retinal pigment epithelial cells have been transplanted into the subretinal space in human subjects. Viral vectors that encode proteins with a strong affinity for vascular endothelial growth factor are in clinical trials. In light of these exciting advances in both genetic and stem cell therapy, the future of AMD treatment shows substantial promise.
Publish Date 2014-11-14 13:11
Citation Nordgren RN, Elkeeb AM, Godley BF. Age-related macular degeneration treatment in the era of molecular medicine. World J Ophthalmol 2014; 4(4): 130-139
URL http://www.wjgnet.com/2218-6239/full/v4/i4/130.htm
DOI http://dx.doi.org/10.5318/wjo.v4.i4.130
Full Article (PDF) WJO-4-130.pdf
Full Article (Word) WJO-4-130.doc
Manuscript File 11635-Review.docx
Answering Reviewers 11635-Answering reviewers.pdf
Copyright License Agreement 11635-Copyright assignment.pdf
Peer-review Report 11635-Peer review(s).pdf
Scientific Misconduct Check 11635-CrossCheck.jpg
Scientific Editor Work List 11635-Scientific editor work list.pdf